Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic  asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study

İnsu YILMAZ; Murat TÜRK; Sakine Nazik BAHÇECİOĞLU; Nuri TUTAR; İnci GÜLMEZ

doi:https://doi.org/10.3906/sag-1912-62

Makale detayları

Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study

Yazarlar:

İnsu YILMAZ | Murat TÜRK | Sakine Nazik BAHÇECİOĞLU | Nuri TUTAR | İnci GÜLMEZ

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2020 Vol.50 Issue 2, pp.433-441

Belge Tipi:

Makale

Yayın Tarihi:

2/2020

Belge Dili:

İngilizce

Document ID (Org No.):

2000749613

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

DOI:

https://doi.org/10.3906/sag-1912-62

Özet:

 

Background/aim: Oral corticosteroid  OCS -dependent severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps  SEACRSwNP  would be a suitable phenotype for mepolizumab treatment. This study evaluated the short-term efficacy of mepolizumab  treatment in OCS-dependent SEA-CRSwNP.  Materials and methods: Baseline and 24th week results [daily OCS doses, asthma exacerbation frequency, asthma control test  ACT   scores, blood eosinophil levels, FEV1   values, and numerical analog scale  NAS  of CRSwNP symptoms] of patients who were treated for  at least 24 weeks with mepolizumab were retrospectively evaluated and compared.  Results: A total of 16 patients were enrolled in the study. Mepolizumab was discontinued in one patient due to side effects. The daily  OCS dosage was reduced from baseline in all patients, and at week 24 OCS was discontinued in 40% of the patients  baseline mean  steroid dose: 9.2 ± 5.2 mg, 24th week: 1.3 ± 1.4 mg; P < 0.001 . The number of asthma exacerbations within 24 weeks significantly  decreased after beginning mepolizumab treatment  2.1 ± 2.7 vs. 0.07 ± 0.26; P = 0.012 , and a significant increase in ACT scores   baseline mean ACT: 18 ± 5.7; 24th week mean ACT: 23.3 ± 3; P = 0.006  was observed despite the decrease in daily OCS dosages. There  was no significant difference in FEV1 values between baseline and week 24. Evaluation of the general symptoms of CRSwNP, as per NAS,  revealed that the baseline mean NAS was 5.6 ± 4.4, and the 24th week mean NAS was 3.2 ± 3.2  P = 0.021 .  Conclusion: This is the first real-life study evaluating the short-term efficacy of mepolizumab treatment on OCS-dependent SEACRSwNP. This study demonstrates that mepolizumab is an effective and safe biologic for the treatment of this severe asthma subphenotype.

Makale detayları

Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study

Yazarlar: İnsu YILMAZ | Murat TÜRK | Sakine Nazik BAHÇECİOĞLU | Nuri TUTAR | İnci GÜLMEZ

Yayıncı: TUBITAK

Dergi: Turkish Journal of Medical Sciences 2020 Vol.50 Issue 2, pp.433-441

Belge Tipi: Makale

Yayın Tarihi: 2/2020

Belge Dili: İngilizce

Document ID (Org No.): 2000749613

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

DOI: https://doi.org/10.3906/sag-1912-62

Sayı

Yazarlar:

İnsu YILMAZ | Murat TÜRK | Sakine Nazik BAHÇECİOĞLU | Nuri TUTAR | İnci GÜLMEZ

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2020 Vol.50 Issue 2, pp.433-441

Belge Tipi:

Makale

Yayın Tarihi:

2/2020

Belge Dili:

İngilizce

Document ID (Org No.):

2000749613

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

DOI:

https://doi.org/10.3906/sag-1912-62